PAR-1 and thrombin signaling are currently being investigated as therapeutic target in GBs.44 In LTS we observed a diverse array of proteins with significantly (P < .05) increased abundance (log-fold change >1) that included HLA-C an important activator of immune response; CASP1 a member of the p53 signaling pathway apoptotic pathway; and surprisingly AKT1 a critical oncogenic regulator of apoptosis (Figure 2B). This evidence concerns the gene TP53 and Guillain-Barre syndrome.